Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$95.74 +0.65%

+$0.46 today

Market cap
$6.49B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.52M

Average 1.55M

ORKA Account Payables

Amounts the company owes suppliers for goods and services received.

Oruka Therapeutics, Inc.NASDAQ: ORKA

Account Payables · Q3 FY2026 · quarter ended Sep 2026

Account payables rises 551.1% from a year ago

Account payables stood at $14.38M at the end of Q3 FY2026, up 551.1% from a year earlier and up 80.8% from the prior quarter. Over 3 fiscal years it compounded at +131.7% a year.

Context

  • Account payables amounted to 1.2% of total assets at the end of Q3 FY2026, up 0.7 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +551.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$14.38M+80.8% QoQ
Last fiscal yearDec 2025
$4.16M+20.0% YoY
Year agoSep 2025
$2.21M+551.1% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+551.1%——
1 year+20.0%——
3-year CAGR+131.7%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
4.16M USD
Year-over-year change
+20.0%
4-year CAGR
+38.9%

Account Payables vs competitors

How ORKA compares with its peers on the latest reported figures

  • ORKA's Sep 2026 account payables of $14.38M is the 3rd highest of the 10 companies compared; the peer median is $7.52M.
  • Its year-over-year change of +551.1% is the highest of 9, against a peer median of +44.8%.
  • Account payables amounts to 1.2% of total assets for ORKA, versus a peer median of 2.3%.
ORKA Competitors Peer median
Account Payables for ORKA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLTXMoonLake ImmunotherapeuticsMar 2026$23.38M +132.4%—5.8%
ACRSAclaris Therapeutics, Inc.Mar 2026$14.73M +131.8%+8.3%7.4%
ORKAOruka Therapeutics, Inc.Sep 2026$14.38M +551.1%+131.7%1.2%
ALMSAlumis Inc. Common StockJun 2026$12.8M -14.6%+80.4%2.3%
XNCRXencor, Inc.Jun 2026$12.65M -31.8%+2.4%1.7%
ANABAnaptysBio, Inc.Mar 2026$7.52M +22.8%+11.6%2.3%
DNTHDianthus Therapeutics, Inc.Jun 2026$6.39M +18.2%+102.7%0.5%
ATTOAttovia Therapeutics, Inc.Jun 2026$6M ——4.7%
ZURAZura Bio LimitedMar 2026$2.08M +66.8%-14.0%0.9%
CNTBConnect Biopharma Holdings LimitedDec 2025$1.96M +474.3%-45.2%3.5%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ORKA) $7.52M+44.8%+8.3%2.3%

Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents53.36M42.45M37.43M61.58M46.94M
Short-term Investments000314.07M290.11M
Net Receivables00000
Inventory00000
Other Current Assets1.06M254K161K1.22M6.81M
Total Current Assets54.42M42.7M37.59M376.87M343.86M
Property, Plant & Equipment (Net)485K368K257K1.04M2.12M
Goodwill00000
Intangible Assets00000
Long-term Investments00018.07M142.54M
Tax Assets00000
Other Non-current Assets18K18K12K43K103K
Total Non-current Assets503K386K269K19.15M144.76M
Total Assets54.92M43.09M37.86M396.02M488.62M
Account Payables1.12M334K03.46M4.16M
Short-term Debt100K103K76K213K619K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.36M522K461K7.33M5.33M
Total Current Liabilities3.5M1.13M637K13.04M15.37M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities383K280K204K755K1.31M
Total Liabilities3.88M1.41M841K13.8M16.69M
Common Stock14K14K14K37K49K
Retained Earnings(173.48M)(183.4M)(188.74M)(83.72M)(189.16M)
Accumulated OCI000(41K)546K
Other Stockholders Equity00000
Minority Interest00000
Total Equity51.04M41.67M37.02M382.22M471.93M
Total Debt483K383K280K968K1.93M
Net Debt(52.88M)(42.06M)(37.15M)(60.61M)(45M)

Oruka Therapeutics, Inc.

NASDAQ:ORKA

Intrinsic Alpha fair value

Locked

Current Price

$95.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.